Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 23 bp deletion in exon1.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-HERC6, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The protein HERC6 also known as HECT and RLD domain containing E3 ubiquitin protein ligase 6 plays a mechanical role in the ubiquitination process. It is a part of the HERC family of ubiquitin ligases characterized by an E3 ubiquitin-ligase domain. HERC6 has an approximate molecular mass of 119 kDa. This protein is ubiquitously expressed across various tissues with especially high levels found in the spleen lung and testis. Its mechanical role involves tagging proteins for degradation which is an important function in regulating protein levels.
Biological function summary
HERC6 contributes to the cellular antiviral response. It participates in the conjugation of the ubiquitin-like protein ISG15 (interferon-stimulated gene 15) to target proteins a modification known as ISGylation. This function supports its participation in host defense mechanisms against viral infections. As an enzyme HERC6 controls ISGylation events either independently or as part of larger protein complexes influencing various cellular processes.
Pathways
The cellular role of HERC6 intersects with the ISGylation pathway. This process involves several enzymes including the E1-activating ISG15 and E2-conjugating enzymes. Additionally HERC6 has connections to the proteasome degradation pathway where ubiquitination marks proteins for breakdown. This protein works in concert with other components like HERC5 another E3 ligase to facilitate antiviral defense through the modification of viral and host proteins.
HERC6 is associated with conditions involving viral infection and immune response. Its dysfunction can potentially impact the efficiency of the immune defense mechanism making the host more susceptible to viruses like influenza or HIV. As it works closely with ISG15 altered expression or activity of HERC6 or ISG15 could play a role in such viral-related diseases. It may also influence cancer development as disruptions in protein degradation pathways are commonly linked with tumor progression highlighting the need for further research into its pathophysiological roles.
